Hu Kang, Zheng Qi-Ming, Wang Ye-Peng, Zhao Meng-Meng, Sun Zhi-Gang
Department of Thoracic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan.
School of Clinical Medicine, Weifang Medical University, Weifang.
Eur J Cancer Prev. 2023 Mar 1;32(2):119-125. doi: 10.1097/CEJ.0000000000000776. Epub 2022 Nov 30.
The expression, activity, and functional role of E-cadherin in adenocarcinoma of the esophagogastric junction (AEG) are unclear. In this research, we evaluated the expression of E-cadherin in AEG, as well as its clinicopathological significance and prognostic value.
A total of 65 AEG samples and 10 normal paracancerous tissues undergoing AEG resection in thoracic surgery were collected. The samples were immunohistochemically examined for expression levels of E-cadherin. The Chi-square test was used to determine if E-cadherin expression correlated with the clinicopathological features of AEG patients. The link between clinicopathological features and 5-year survival rates was investigated using Kaplan-Meier survival curves and multifactorial Cox regression analysis.
In AEG tissues, E-cadherin expression was considerably reduced. Differentiation grade ( P = 0.013), infiltration depth ( P = 0.033), and clinicopathological stage ( P = 0.045) were substantially linked to the level of E-cadherin expression. Five-year survival rates of AEG patients were affected by E-cadherin expression ( P = 0.037), tumor differentiation ( P = 0.010), lymph node metastasis ( P < 0.001), and clinicopathological stage ( P = 0.037). Tumor differentiation ( P = 0.033) and lymph node metastasis ( P = 0.001) were independent risk factors for shorter overall survival.
E-cadherin expression in AEG was significantly decreased, which was strongly related to tumor differentiation, infiltration, and clinicopathological stage. An E-cadherin deficiency would lead to poor prognosis in AEG patients. E-cadherin may play a crucial role in AEG invasion and metastasis. Low expression of E-cadherin may be a potential early biomarker and overall survival predictor for AEG patients.
食管胃交界腺癌（AEG）中E-钙黏蛋白的表达、活性及功能作用尚不清楚。在本研究中，我们评估了E-钙黏蛋白在AEG中的表达及其临床病理意义和预后价值。
收集65例接受胸外科手术切除的AEG样本及10例正常癌旁组织。采用免疫组织化学方法检测样本中E-钙黏蛋白的表达水平。采用卡方检验确定E-钙黏蛋白表达是否与AEG患者的临床病理特征相关。使用Kaplan-Meier生存曲线和多因素Cox回归分析研究临床病理特征与5年生存率之间的关系。
在AEG组织中，E-钙黏蛋白表达显著降低。分化程度（P = 0.013）、浸润深度（P = 0.033）和临床病理分期（P = 0.045）与E-钙黏蛋白表达水平显著相关。AEG患者的5年生存率受E-钙黏蛋白表达（P = 0.037）、肿瘤分化（P = 0.010）、淋巴结转移（P < 0.001）和临床病理分期（P = 0.037）的影响。肿瘤分化（P = 0.033）和淋巴结转移（P = 0.001）是总生存期缩短的独立危险因素。
AEG中E-钙黏蛋白表达显著降低，这与肿瘤分化、浸润及临床病理分期密切相关。E-钙黏蛋白缺乏会导致AEG患者预后不良。E-钙黏蛋白可能在AEG侵袭和转移中起关键作用。E-钙黏蛋白低表达可能是AEG患者潜在的早期生物标志物和总生存期预测指标。
